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Introduction: Endothelial colony-forming cells (ECFCs) significantly improve tissue repair by providing regeneration
potential within injured cardiovascular tissue. However, ECFC transplantation into ischemic tissue exhibits limited
therapeutic efficacy due to poor engraftment in vivo. We established an adequate ex vivo expansion protocol and
identified novel modulators that enhance functional bioactivities of ECFCs.
Methods: To augment the regenerative potential of ECFCs, functional bioactivities of hypoxia-preconditioned
ECFCs (hypo-ECFCs) were examined.
Results: Phosphorylations of the JAK2/STAT3 pathway and clonogenic proliferation were enhanced by short-term
ECFC culturing under hypoxia, whereas siRNA-targeting of STAT3 significantly reduced these activities. Expression
of BCL3, a target molecule of STAT3, was increased in hypo-ECFCs. Moreover, siRNA inhibition of BCL3 markedly
reduced survival of ECFCs during hypoxic stress in vitro and ischemic stress in vivo. In a hindlimb ischemia model
of ischemia, hypo-ECFC transplantation enhanced blood flow ratio, capillary density, transplanted cell proliferation
and survival, and angiogenic cytokine secretion at ischemic sites.
Conclusions: Hypoxia preconditioning facilitates functional bioactivities of ECFCs by mediating regulation of the
STAT3-BCL3 axis. Thus, a hypoxic preconditioned ex vivo expansion protocol triggers expansion and functional
bioactivities of ECFCs via modulation of the hypoxia-induced STAT3-BCL3 axis, suggesting that hypo-ECFCs offer
a therapeutic strategy for accelerated neovasculogenesis in ischemic diseases.Introduction
Patients with peripheral arterial disease are at risk for
progression to severe limb ischemia. Therapeutic angio-
genesis is important for blood perfusion in ischemic
limb tissue and tissue regeneration after critical ische-
mia [1, 2]. Stem cell-based therapy holds great promise
for therapeutic angiogenesis in ischemic limb diseases
[3]. Circulating endothelial progenitor cells (EPCs), an
angiogenesis potential-initiating subpopulation, were
originally identified in adult peripheral blood, and bone
marrow (BM)-derived stem/progenitor cells are required
for several activities of EPCs. EPCs have the ability to
self-renew in the BM, differentiate into mature endothelial* Correspondence: hjhan@snu.ac.kr
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system. Furthermore, they are recruited to sites of
neovascularization [4]. Accumulating evidence sug-
gests that transplantation of human circulating EPCs
enhances vascular repair and regeneration following
ischemic diseases [5, 6].
Hypoxia is known to regulate cellular processes and
signal transduction via the expression of hypoxia indu-
cible factor-1α (HIF-1α), which is regulated by cellular
O2 concentration and determines the transcriptional
activity of HIF-1 [7]. HIF-1α exerts significant effects
on the bioactivities of both cancer and stem cells by
stimulating cell proliferation, vascular endothelial growth
factor (VEGF) expression, and angiogenesis [8, 9]. The
activity and stability of HIF-1α are known to be modu-
lated by STAT3. Activated STAT3 increases HIF-1α
protein levels and stability by accelerating de novo syn-
thesis and blocking degradation [10]. Pawlus et al. [11]le distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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moters of HIF-1 and HIF-2 target genes, interacting
with HIF-1α to activate HIF-1 target gene promoters,
even when overexpressed. Recently, the relationship
between STAT3 and BCL3 has been demonstrated in
carcinoma and tumor survival [12]. Furthermore, BCL3
has been suggested to be involved in the pathogenesis
of solid tumors such as nasopharyngeal carcinoma [13]
and breast cancer [14]. Stem and cancer cells share
many similarities in gene expression, cellular processes,
and signal transduction pathways, but few, if any, stud-
ies have evaluated the effects of the STAT3-BCL3 axis
in normal stem cells. In addition, it is not clear whether
hypoxic culture is beneficial to each type of stem cell
owing to their various origins and differences in oxygen
sensitivity [15].
After localization to ischemic tissue, EPCs encounter
severe hypoxic conditions, ranging from 0.4 to 2.3 %
O2, often resulting in apoptosis [16]. However, before
exposure to severe conditions at the site of ischemic
injury, preconditioning of cells in less severe hypoxic
conditions (1–3 % O2) is able to circumvent hypoxia-
induced apoptosis through induction of p42/44 mitogen-
activated protein kinases [17]. Previous studies have
shown that culture in hypoxic conditions (2–7 % O2) is
beneficial for EPCs, as this oxygen tension is similar to
that in the physiological niche for EPCs in the BM; it
maintains their viability and enhances the proliferation
rate of mesenchymal stem cells (MSCs) via expression
of fibronectin [18], collagen I [19], connexin 43 [19],
CXCR4 [20] and angiogenic cytokines [21]. In this
study, we hypothesized that hypoxic culture would pro-
vide additional benefits to endothelial colony-forming cells
(ECFCs) over normoxic culture; thus, we attempted to
establish a general protocol for the high proliferation of
ECFCs within a hypoxic culture. Specifically, we deter-
mined the effects of hypoxic preconditioned culture on
the clonogenic and proliferative potential of ECFCs, as
well as on their ability to promote therapeutic vasculo-
genesis in ischemic limbs. Furthermore, we investigated
the effects of hypoxic preconditioning on ECFC prolif-
eration, survival, and VEGF secretion via regulation of
the BCL3-STAT3 circuit.Methods
Animal
Experiments were performed on male 8-week-old Balb/C
nude mice (Orient Bio, Seoul, Korea [22]) maintained
under a 12-h light/dark cycle and in accordance with the
regulations of Soonchunhyang University. All procedures
were approved by guidelines of the Institutional Animal
Care and Use Committee of Soonchunhyang University,
Seoul Hospital, Korea (IACUC2013-5).Isolation, cell culture, and characterization of ECFCs
Isolation and culture of ECFCs was performed according
to previously described methods, but with minor modifi-
cations [23]. Human umbilical cord blood (HUCB) was
collected from three healthy volunteers after obtaining
informed consent from all subjects according to the
protocol approved by the Institutional Review Board of
the Pusan National University Yangsan Hospital, Korea
(IRB No. 2012–19). HUCB samples were collected from
fresh placentas with attached umbilical cords. Human
mononuclear cells (MNCs) were obtained as previously
described, with minor modifications [24–26]. MNCs
were isolated from HUCB by density gradient centrifu-
gation with a Ficoll separating solution (Amersham Bio-
sciences, Uppsala, Sweden). Freshly isolated MNCs were
cultured on 100-mm dishes coated with 1 % gelatin
(Sigma, St. Louis, MO, USA) and cultured in endothelial
basal media (EBM)-2 (Lonza, Walkersville, MD, USA)
supplemented with 5 % fetal bovine serum (FBS), human
VEGF, human basic fibroblast growth factor (bFGF),
human epidermal growth factor (EGF), human insulin-
like growth factor-1 (IGF-1), ascorbic acid, and GA-1000
(complete EGM-2 medium). After 4 days, nonadherent
cells were discarded and fresh culture medium was ap-
plied. Cultures were maintained for another 3 days, and
extended culture was continued until the appearance of
spindle-shaped colonies (~14–21 days) by refreshing
with fresh EGM-2 media. The medium was changed
daily for 7 days, and then every 2 days until the first
passage. The ECFC (passage 6) population was deter-
mined via flow cytometry analysis using labeled endothe-
lial cell markers (i.e., anti-human CD31 (PECAM-1; BD
Pharmingen, San Diego, CA, USA), anti-human CD144
(VE-cadherin; BD Pharmingen), anti-human von Will-
ebrand factor (vWF; Santa Cruz Biotechnology, Dallas,
TX, USA), and anti-human Tie-2 (BD Pharmingen)).
Stained cells were analyzed using a fluorescence-
activated cell sorter (FACS; BD FACS Canto II, San
Jose, CA, USA). Flow cytometry analysis was performed
according to previously described methods with minor
modifications [27]. For FACS analysis, soon after hyp-
oxic preconditioning, we performed fixation for 24 h to
minimize reperfusion stress. ECFCs expressed high
levels of the endothelial cell markers CD31, CD144, vWF,
and Tie-2 following expansion under both normoxic and
hypoxic conditions for 24 h. Each experiment was re-
peated at least three times.Hypoxia and hypoxic preconditioning
To study the effect of hypoxia or hypoxic preconditioning
on ECFCs, ECFCs were incubated in a Modular Incubator
Chamber (IB Science, Daejeon, Korea) that maintained a
gas mixture composed of 93 % N2, 5 % CO2, and 2 % O2.
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cells for 24 h at 37 °C under hypoxic conditions (2 % O2).
Single-cell assays
Flow cytometry (BD FACS Aria II) was used to place
one single ECFC into a well of a 96-well flat-bottom
tissue culture plate precoated with 1 % gelatin and con-
taining 200 μL complete EGM-2 media. Individual wells
were examined with an inverted phase contrast micro-
scope at 40× magnification to ensure that only one cell
had been placed into each well. Cells were cultured
under normoxic (94.5 % air and 5.5 % CO2) or hypoxic
(93 % N2, 5 % CO2, and 2 % O2) conditions in a hu-
midified incubator. At day 10, each well was examined
for ECFC growth. To assess the clonogenicity of single
ECFCs, we used phase contrast microscopy to score all
colony-forming wells per 96-well plate. To enumerate
the number of cells per colony-forming well, we trypsi-
nized colony-forming cells and counted them with a
hemocytometer [23].
Intracellular accumulation of calcein AM
Single ECFCs were placed into the wells of a 96-well
flat-bottom tissue culture plate and incubated with
normoxia or hypoxia preconditioning for 10 days. Sub-
sequently, 50 μL of 1 μM calcein AM (Invitrogen,
Carlsbad, CA, USA) was added to 100 μL of the culture
medium, which was contained in each microplate well.
After incubation with calcein AM for 30 min at 37 °C,
the medium was removed by aspiration. The intracellu-
lar accumulation of calcein AM was then visualized and
quantified by using a fluorescence microscope (Nikon,
Tokyo, Japan).
Small interfering RNA transfection of cells
ECFCs were grown to 75 % confluency and then trans-
fected for 24 h with SMART pool small interfering RNAs
(siRNAs) specific to either STAT3 or BCL3 (both at 100
nM) using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s instructions.
Western blot analysis
Total protein was extracted using RIPA Lysis Buffer
(Thermo Scientific, Rockford, IL, USA). Cell lysates were
separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, and proteins were transferred to polyviny-
lidene fluoride membranes (PVDF; Millipore, Billerica,
MA, USA). The membranes were blocked with 5 % skim
milk and incubated with primary antibodies against
human-specific BCL3, cleaved caspase-3, human VEGF,
STAT3, phospho-STAT3, α-tubulin, and β-actin (Santa
Cruz Biotechnology). After incubation of the membranes
with peroxidase-conjugated secondary antibodies (Santa
Cruz Biotechnology), bands were visualized usingenhanced chemiluminescence (ECL) reagents (Amersham
Biosciences).
Human VEGF assay
Human VEGF concentrations in cell culture media were
determined with the human VEGF enzyme-linked im-
munosorbent assay (ELISA) reagents (BD Pharmingen)
according to the manufacturer’s instructions. Absorbance
was read at 450 nm on a spectrophotometric ELISA plate
reader. Results are expressed as the mean concentration
of triplicate cultures. Values were converted from absolute
counts to a percentage of the control to allow for com-
parison between experimental groups.
Cell transplantation in a murine hindlimb ischemia model
In the murine hindlimb ischemia model, ischemia was
induced by ligation of the proximal femoral artery and
boundary vessels of the mice. No later than 6 h after
surgery, phosphate-buffered saline (PBS), nor-ECFCs,
hypo-ECFCs, si-STAT3 hypo-ECFCs, and si-BCL3 hypo-
ECFCs were injected intramuscularly into the ischemic
thigh area (5 × 105 cells in 100 μL PBS per mouse, five
mice per treatment group). Blood perfusion was assessed
by measuring the ratio of the ischemic (left) limb blood
flow/nonischemic (right) limb blood flow on postopera-
tive days 0, 4, 9, 18, and 28 using laser Doppler perfu-
sion imaging (LDPI; Moor Instruments, Wilmington,
DE, USA).
Histopathology and immunohistochemistry
After 3 and 28 days following ECFC transplantation, the
ischemic thigh areas were removed and fixed with 4 %
paraformaldehyde (Affymetrix, Santa Clara, CA, USA).
Each tissue sample was embedded in paraffin. For histo-
logical analysis, samples were stained with hematoxylin
and eosin (H&E). Immunofluorescence staining was per-
formed using primary antibodies against mouse-specific
(to confirm mouse vasculature) or human-specific (to
confirm human ECFC-derived vessel formation) CD31,
α-smooth muscle actin (α-SMA), human VEGF, phospho-
STAT3, caspase-3, PCNA, Ki67 (Santa Cruz), human-
specific CD31 (Novus Biologicals, Colorado, USA), and
human nuclear antigen (HNA; Millipore) and second-
ary antibodies Alexa-488 and Alexa-594 (Life Tech-
nologies, Carlsbad, CA, USA). Nuclei were stained with
4′,6-diamidino-2-phenylindole phenylindole (DAPI; Vec-
tor Laboratories, Burlingame, CA, USA). Immunostained
slides were imaged by confocal microscopy (Olympus,
Japan).
Hematoxylin staining
Single ECFCs in the wells of a 96-well flat-bottom tis-
sue culture plate were incubated with normoxia or hyp-
oxia preconditioning for 10 days, after which the
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v) paraformaldehyde in PBS for 40 min. The ECFCs
were then washed twice more in PBS (15 min per wash)
and subsequently immersed in Harris hematoxylin so-
lution (Sigma) for 10 min. After a 20 min wash with
PBS, the ECFC plates were photographed using a digital
camera (Olympus).
Statistical analyses
The results are expressed as mean ± SD. All experimental
results were analyzed by analysis of varaince, and in some
cases were followed by a comparison of the treatment
means with the control using a Bonnferroni-Dunn test.
Statistical significance was established at P values < 0.05.
Results
Characterization of ECFC surface markers in response to
hypoxia
To characterize surface markers of ECFCs in response
to hypoxia, we established FACS analysis to assess
various surface markers, including progenitor markers
(CD34, c-Kit, and CXCR4), endothelial lineage markers
(VEGFR2, CD31, CD144, and Tie-2), and hematopoietic
lineage markers (CD11b, CD14, and CD45). The expres-
sion of progenitor markers and VEGFR2 was significantly
increased in hypo-ECFCs compared with nor-ECFCs
(Fig. 1a). Both hypo- and nor-ECFCs did not express
hematopoietic lineage markers.
Promotion of the proliferative and clonogenic potential
of ECFCs in response to hypoxia
To investigate the effect of hypoxia on ECFCs, we devel-
oped an assay to quantify the proliferative and clono-
genic potential of single cord blood derived from ECFCs
(Fig. 1b). Remarkably, the average number of single cells
undergoing at least one cell division was increased
1.3-fold for hypo-ECFCs compared with nor-ECFCs
(Fig. 1c, d). In addition, the average number of ECFC
colonies per plate of hypo-ECFCs was significantly
greater than nor-ECFCs (Fig. 1e, f ). These findings
suggest that hypoxia influences the maintenance ability
of ECFCs in vitro.
Involvement of the JAK2/STAT3 pathway in hypoxic
preconditioning of ECFC proliferative and clonogenic
potential
To assess the involvement of JAK2/STAT3 in hypoxic
preconditioning of the proliferative and clonogenic po-
tential of ECFCs, hypoxia-induced phosphorylation of
JAK2 and STAT3 was examined by western blot. Hyp-
oxia increased JAK2 and STAT3 phosphorylation in a
time-dependent manner (Fig. 2a). We then examined
whether STAT3 plays a positive role in the regulation of
the proliferative and clonogenic potential in ECFC. Thehypoxia-induced increase in STAT3 phosphorylation
was attenuated by STAT3-specific siRNAs (Fig. 2b). Cor-
respondingly, siRNA targeting of STAT3 in hypoxic cells
decreased single-cell division as well as the number of
colonies (Fig. 2c–f ). This suggests that hypoxia increases
proliferative and clonogenic potential through the activa-
tion of STAT3.
Involvement of the STAT3 pathway in hypo-ECFC survival
in ischemic tissue
In the previous in vitro experiments, we demonstrated
that the culture of ECFCs in hypoxic conditions acti-
vated the STAT3 signaling pathway and increased their
proliferative potential. We hypothesized that hypoxic-
preconditioned culturing of ECFCs (hypo-ECFCs) would
be beneficial for repairing the damaged tissue in the
hindlimb ischemia injury model by providing cells with a
better proliferative rate to the site of ischemic injury. To
evaluate the in vivo regulation of the STAT3 pathway,
we transplanted nor-ECFCs and hypo-ECFCs into nude
mice with hindlimb ischemia. After 3 days, ischemic
tissues transplanted with hypo-ECFCs exhibited signifi-
cantly higher levels of STAT3 activation than tissues
transplanted with nor-ECFCs (Fig. 3a). Next, the dis-
tribution of STAT3 in hypo-ECFCs was evaluated.
Hypo-ECFCs exhibited an increase in the number of
phospho-STAT3/HNA/DAPI-positive cells in the ECFC
population (Fig. 3b). Accordingly, more proliferating cell
nuclear antigen (PCNA)-positive cells were found in tissue
transplanted with hypo-ECFCs than that transplanted
with nor-ECFCs (Fig. 4a, c). HNA and proliferating cell
marker (Ki-67)-double positive cells were more abundant
at 3 days in tissue receiving hypo-ECFCs than that receiv-
ing nor-ECFCs (Fig. 4b, d). However, STAT3-specific
siRNA-transfected hypo-ECFCs (si-STAT3/hypo-ECFCs)
displayed poor proliferation in ischemic tissue.
STAT3 upregulates BCL3 expression and promotes ECFC
survival during ischemic stress
Next, we determined whether hypoxia-induced activa-
tion of STAT3 led to the activation of BCL3, a known
target of STAT3 [28], subsequently promoting cell
survival [17]. Normoxic cells were found to express a
very low level of BCL3, whereas hypoxic cells exhibited
elevated BCL3 expression (Fig. 5a). We examined
whether STAT3 was involved in the regulation of BCL3
expression. As expected, the hypoxia-induced increase
in BCL3 expression was attenuated by STAT3-specific
siRNAs (Fig. 5b). Additionally, siRNA-targeting BCL3
in long-term hypoxic conditions (96 h) in the presence
of a high concentration of H2O2 (10
−3 M) increased
cleaved caspase-3 levels, a marker for apoptosis, relative
to hypoxia alone (Fig. 5c, d). Furthermore, immuno-
fluorescence staining for caspase-3 and HNA in
Fig. 1 Enhanced proliferative and clonogenic potential of endothelial colony-forming cells (ECFCs) after hypoxic preconditioning. a
Characterization of ECFC surface markers after hypoxic preconditioning for 24 h. FACS analysis was performed using various surface markers,
including progenitor markers (CD34, c-Kit, and CXCR4), endothelial lineage markers (VEGFR2, CD31, CD144, and Tie-2), and hematopoietic
markers (CD11b, CD14, and CD45). b Schematic of single-cell assays using ECFCs. c Representative photomicrograph of the cell clusters derived from a
single ECFC. d The number of cells per nor-ECFC or hypo-ECFC colony that underwent at least one cell division after 10 days of culture (*P < 0.05 vs.
nor-ECFCs). e Image of hematoxylin-stained plate with a representative ECFC colony, and f a graph of the number of ECFC colonies per 96-well plate.
The example shown is representative of four independent experiments. **P < 0.01 vs. nor-ECFCs
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that apoptotic ECFCs were significantly reduced after
transplantation with hypo-ECFCs compared to after
transplantation with nor-ECFCs, but BCL3-specific
siRNA-transfected hypo-ECFCs (si-BCL3/hypo-ECFCs)
displayed poor survival in ischemic tissue (Fig. 5e, f ).
These data suggest that STAT3 increases cell survival
and prevents apoptosis via the induction of BCL3.STAT3 promotes upregulation of VEGF secretion in
ischemic tissue
Transplantation of ECFCs into ischemic tissue enhances
the paracrine secretion of angiogenic growth factors
such as VEGF. To determine whether VEGF was se-
creted by hypo-ECFCs, we analyzed the secretion and
expression of VEGF by ELISA and western blot analysis.
Hypo-ECFCs clearly exhibited higher secretion and
Fig. 2 Activation of the JAK2/STAT3 signaling pathway in hypo-ECFCs and the regulation of proliferative, clonogenic potential. a Endothelial
colony-forming cells (ECFCs) were exposed to hypoxia for 0–24 h, and JAK2, p-JAK2, STAT3, and p-STAT3 were detected by western blot analysis.
b ECFCs were transfected with STAT3-siRNA and scramble siRNA for 48 h prior to hypoxia exposure for 24 h. p-STAT3 was detected by western
blot analysis. c Representative photomicrograph of the cell clusters derived from single nor-ECFCs, hypo-ECFCs, STAT3-siRNA-transfected
hypo-ECFCs (si-STAT3/hypo-ECFCs), and scramble siRNA-transfected hypo-ECFCs, as well as d a graph of the number of these cells per
colony. e Images of hematoxylin-stained plates with representative nor-ECFC, hypo-ECFC, si-STAT3/hypo-ECFC, and scramble siRNA-transfected
hypo-ECFCs colonies, as well as f graphs of the number of these colonies per 96-well plate. The example shown is representative of four independent
experiments. **P < 0.01 vs. nor-ECFCs; ##P < 0.01 vs. hypo-ECFCs; $$P < 0.01 vs. si-STAT3/hypo-ECFC
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evaluate whether si-STAT3/hypo-ECFCs alter the secre-
tion of VEGF in ischemic tissue, we transplanted hypo-
ECFCs, nor-ECFCs, and si-STAT3/hypo-ECFCs into the
hindlimb ischemic injury site. Western blot analysis
revealed that VEGF expression within this tissue was
elevated after hypo-ECFC transplantation, while VEGF
expression following transplantation with si-STAT3/
hypo-ECFCs or nor-ECFCs was only slightly higher than
that of the PBS-treated control (Fig. 6c). Moreover,
VEGF expression was detected by immunofluorescence
staining in hypo-ECFCs at 3 days after transplantation,whereas minimal VEGF expression was detected in
tissue transplanted with si-STAT3/hypo-ECFCs (Fig. 6d).
These results suggested that hypo-ECFCs were able to
induce the secretion of VEGF, and that the activation of
STAT3 was responsible for VEGF induction.
Hypoxic preconditioning of ECFCs promotes vascular
repair in ischemic limbs
To examine whether hypo-ECFCs would promote neo-
vascularization in vivo, a hindlimb ischemia mouse
model was used and analyzed with LDPI. Ischemia was
induced in the mouse hindlimb, and equal numbers of
Fig. 4 STAT3-mediated transplanted hypo-ECFC proliferation in ischemic tissues. a Immunofluorescence staining for proliferating cell nuclear
antigen (PCNA, green) in ischemic hindlimb after transplantation of nor-ECFCs, hypo-ECFCs, si-STAT3/hypo-ECFCs, or scramble siRNA/hypo-ECFCs
(scale bar: 100 μm). b Co-immunofluorescence staining to detect Ki-67 (a proliferation marker, red) and nor-ECFCs, hypo-ECFCs, si-STAT3/
hypo-ECFCs, or scramble siRNA/hypo-ECFCs (human nuclear antigen (HNA)-positive cells, green). DAPI (blue) was used for nuclear staining
(scale bar: 50 μm). c Bar graph shows the results of number of PCNA+ cells 3 days after transplantation. d Quantitative analysis of Ki-67/
HNA/DAPI triple-positive cells 3 days after transplantation of nor-ECFCs, hypo-ECFCs, si-STAT3/hypo-ECFCs, or scramble siRNA/hypo-ECFCs.
**P< 0.01 vs. nor-ECFCs; ##P< 0.01 vs. hypo-ECFCs; $$P< 0.01 vs. si-STAT3/hypo-ECFC. ECFC endothelial colony-forming cell, PBS phosphate-buffered saline
Fig. 3 STAT3 is activated in hypo-ECFCs under ischemia. a Western blot analysis was performed to determine the levels of p-STAT3 in hindlimb
ischemia injury after transplantation of hypo-ECFCs. b Co-immunofluorescence staining was used to detect p-STAT3 and hypo-ECFCs (human
nuclear antigen (HNA)-positive cells, red). DAPI (blue) was used for nuclear staining. White color indicates merged color with green and red colors.
Arrows indicate p-STAT3+/HNA+/DAPI+ cells. ECFC endothelial colony-forming cell, PBS phosphate-buffered saline
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Fig. 5 Modulation of the STAT3-BCL3 axis enhances survival induced by ischemic stress. a Endothelial colony-forming cells (ECFCs) were exposed
to hypoxia for various times (0–24 h). BCL3 expression was detected by western blot analysis. b ECFCs were transfected with STAT3-siRNA for 48 h
prior to exposure to hypoxic conditions for 24 h. BCL3 was detected by western blot analysis. c ECFCs were transfected with BCL3-siRNA for 48 h
prior to exposure to hypoxic conditions for 96 h. Cleaved caspase-3 was detected by western blot analysis. d ECFCs were transfected with BCL3-siRNA
for 48 h prior to treatment with H2O2 (10
−3 M) for 8 h followed by western blot analysis for cleaved caspase-3. e Co-immunofluorescence staining was
used to detect apoptosis (caspase-3, an apoptosis marker, red) and nor-ECFCs, hypo-ECFCs, si-BCL3/hypo-ECFCs, or scramble siRNA/hypo-ECFCs (human
nuclear antigen (HNA)-positive cells, green). DAPI (blue) was used for nuclear staining. Arrows indicate caspase-3+/HNA+/DAPI+ cells (scale bar: 50 μm). f
Quantitative analysis of caspase-3/HNA/DAPI triple-positive cells conducted 3 days after transplantation of nor-ECFCs, hypo-ECFCs, si-BCL3/hypo-ECFCs, or
scramble siRNA/hypo-ECFCs. **P< 0.01 vs. nor-ECFCs; ##P< 0.01 vs. hypo-ECFCs; $$P< 0.01 vs. si-STAT3/hypo-ECFC; n = 10
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laser Doppler perfusion measurements revealed that the
blood flow in the ischemic right hindlimb was lower
than that in the control left hindlimb. The hypo-ECFC
treatment group displayed increased hindlimb perfusion
compared with the nor-ECFC group (Fig. 7a, b). Trans-
plantation of hypo-ECFCs promoted angiogenesis within
ischemic tissue. Immunofluorescence staining for
CD31 and quantification of capillary density was sig-
nificantly enhanced after transplantation with hypo-ECFC compared to transplantation with nor-ECFCs
(Fig. 7c, d). To elucidate that transplanted human
ECFCs were involved in vessel formation, immuno-
fluorescent staining for human-specific CD31 was per-
formed. Human-specific CD31-positive cells were
more abundant in animals 28 days after treatment
with hypo-ECFCs than in those treated with nor-
ECFCs (Fig. 7e, f ). Similarly, immunofluorescence
staining for α-SMA showed that arteriole formation was
enhanced by transplanting hypo-ECFC (Fig. 7g, h). H&E
Fig. 6 Transplanted hypo-ECFCs enhance secretion of vascular endothelial growth factor (VEGF) in ischemic limb muscle via STAT3 signaling.
a, b ECFCs, si-STAT3-ECFCs, and scramble siRNA hypo-ECFCs were cultured in normoxic or hypoxic conditions for 12 h, and VEGF levels were
determined by using ELISA and western blot analysis. The results are expressed as the mean ± SD. c Western blotting analyses of VEGF conducted
3 days after transplantation of nor-ECFCs, hypo-ECFCs, si-STAT3/hypo-ECFCs, or scramble siRNA/hypo-ECFCs. d Immunofluorescence staining
for VEGF in ischemic tissues conducted 3 days after transplantation of nor-ECFCs, hypo-ECFCs, si-STAT3/hypo-ECFCs, or scramble siRNA/
hypo-ECFCs (n = 7). **P < 0.01 vs. nor-ECFCs; ##P < 0.01 vs. hypo-ECFCs; $$P < 0.01 vs. si-STAT3/hypo-ECFC. ECFC endothelial
colony-forming cell
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ation of hypo-ECFCs compared with the blood flow ob-
served following transplantation of nor-ECFCs (Fig. 7i).
Discussion
In the present study, we demonstrated that hypoxia in-
creased the proliferative, clonogenic, and survival poten-
tial of ECFCs via JAK2/STAT3 phosphorylation and
STAT3-induced expression of BCL3. Although resident
human EPCs have been reported to contribute signifi-
cantly to vascular repair at sites of ischemia and are cap-
able of differentiating into endothelial cells [24–26], the
development of a protocol that exploits the advantages
of culture methods to improve the quality and quantity
of EPCs for clinical applications is necessary. There is
accumulating evidence that modulation of retroviraltransduction of the human telomerase gene [29] and the
combination of growth factors in serum-free culture [30]
can enhance the progenitor properties of EPCs. All of
these methods, however, result in genetic modification
or the enrichment of cells with oncogenic potential [31].
The protocol presented herein takes advantage of the
specific ability of EPCs to survive under hypoxia without
modification that could lead to any aberrant genetic and
biological alterations [32]. Based on their normal
morphology and intact genetic integrity, as well as the
enhancement of their angiogenic potential upon trans-
plantation, the protocol presented herein is safe to use
for the preparation of ECFCs for clinical applications.
To our knowledge, this study is the first to demonstrate
that hypoxia improves the functionality of ECFCs.
These effects resulted in the functional activation of
Fig. 7 (See legend on next page.)
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Fig. 7 Hypoxic preconditioning of endothelial colony-forming cells (ECFCs) enhances functional recovery after limb ischemia. a Improvements in
blood flow recovery were evaluated using LDPI analysis in the ischemic limbs of 8-week-old Balb/C nude mice injected with phosphate-buffered
saline (PBS), nor-ECFCs, and hypo-ECFCs at 0, 4, 9, 18, and 28 days post-surgery. b The ratio of blood perfusion (blood flow of the left ischemic
limb/blood flow of the right non-ischemic limb) was measured in the three groups. Values represent means ± SD. **P < 0.01 vs. PBS group; ##P < 0.01
vs. nor-ECFCs. c, e Representative images of mouse-specific CD31+ and human-specific CD31+ tissue at 28 days after transplantation of nor-ECFC or
hypo-ECFC into hindlimb ischemia (scale bar: 50 μm; n = 10). g Representative images of arteriole structures (α-SMA staining for arterioles, red
fluorescence)-positive tissue at 28 days after transplantation of nor-ECFC or hypo-ECFC into hindlimb ischemia (scale bar: 50 μm; n = 10). Quantification
(d, f, h) represents cell numbers analyzed per high-power field (HPF). Values represent means ± SD. **P < 0.01 vs. nor-ECFCs; ##P < 0.01 vs. hypo-ECFCs. i
H&E staining was used to produce histological images of tissue 28 days after transplantation of nor-ECFCs or hypo-ECFCs into hindlimb ischemia
Fig. 8 Schematic representation of proposed mechanisms by which
hypoxia increases clonogenic and proliferative potential, and enhances
hypo-ECFC-mediated neovasculogenesis. Hypoxic preconditioning
increases the clonogenic and proliferative potential of endothelial
colony-forming cells (ECFCs) via the STAT3 pathway and augments the
survival of ECFCs via STAT3-mediated BCL3 and vascular endothelial
growth factor (VEGF) expression. These effects enhance ECFC-mediated
neovasculogenesis in ischemic diseases
Lee et al. Stem Cell Research & Therapy  (2015) 6:139 Page 11 of 13ECFCs by hypoxia, thereby facilitating ECFC-mediated
neovascularization and functional recovery in ischemic
disease.
Previous reports have demonstrated that STAT3 con-
tributes to the hypoxia-induced enhancement of self-
renewal in embryonic stem cells [33, 34] and other
adult stem cells [35, 36], as well as hypoxia-induced angio-
genesis [37], hypoxia preconditioned human EPC-induced
neovascularization [32], and tumor vasculature [38]. In
the present study, consistent with these previous reports,
hypoxic culture of ECFCs increased stem cell surface
markers (CD34, c-Kit, and CXCR4) and VEGFR2, and
augmented the proliferative and clonogenic potential of
ECFCs by enhancement of VEGF expression through the
modulation of the STAT3 signaling pathway. However, in
the study by Hofmann et al. [39], ECFC function de-
creased in response to hypoxic conditions (1 % O2), and
this ECFC bioactivity was rescued by co-culture with
MSC/progenitor cells. This discrepancy in response of
hypoxia on ECFC could be explained by differences in the
oxygen concentration and duration of hypoxia. Although
hypoxic culture conditions of at least 2 % are indispens-
able to robust human ESC clone recovery and self-
renewal and multipotency of ESCs, a long-term, severe
hypoxic condition resulted in cell damage and apoptosis
[40, 41]. In addition, we previously reported that the hyp-
oxic preconditioning increased proliferation of human
EPCs through augmentation of S phase and cell cycle
regulatory proteins expression [41]. Furthermore, Ingram
et al. [23] identified high proliferative potential endothelial
colony-forming cells (HPP-ECFCs) in HUCB. The in-
creased proliferative and clonogenic potential of ECFCs
suggests that hypoxic preconditioning induces augmenta-
tion of the HPP-ECFC population via the STAT3-BCL3
circuit. Importantly, we focused on BCL3 expression by
the regulation of STAT3. BCL3 was increased by phos-
phorylation of STAT3 and facilitated ECFC survival
in vitro and in vivo. BCL3 is a proto-oncogene that
belongs to the IκB family, and its aberrant expression was
first reported in chronic B cell lymphocytic leukemia [42].
Elevated levels of BCL3 have been detected in a large
number of cancers, including breast cancer [14], and it
has been reported that BCL3 can have an anti-apoptotic
effect in cancer [28]. Although several studies haveexamined the function and regulation of BCL3, little is
known about the mechanism of BCL3 in physiological
and pathophysiological conditions, especially in stem cells.
Our findings revealed that BCL3 was upregulated under
hypoxic conditions, resulting in the prevention of apop-
tosis induced by ischemic stress both in vitro and in vivo.
The present study demonstrates, for the first time, that
Lee et al. Stem Cell Research & Therapy  (2015) 6:139 Page 12 of 13BCL3 could play a pivotal role in proliferation, clonogenic
potential, and survival of ECFCs by the direct regulation
of hypoxia-induced STAT3.
ECFCs and their therapeutic capabilities have been
explored in previous studies. Although ECFCs have
been shown to differentiate into endothelial cells in vivo
[26, 43–45], the leading concept is that ECFCs mediate
tissue repair through the secretion of angiogenic factors.
Some evidence suggests that hypoxia may enhance the
secretion of angiogenic factors from ECFCs, thus indi-
cating another possible mechanism by which hypoxic
preconditioning enhances the tissue-repair potential of
ECFCs. ECFCs have been demonstrated to secrete mul-
tiple proangiogenic factors, including VEGF, FGF, and
placental growth factor, in response to hypoxic stimula-
tion [46]. In this report, we show that the expression of
human VEGF was higher in hypo-ECFCs than in nor-
ECFCs. In the mouse hindlimb ischemia model, trans-
planted hypo-ECFCs exhibited higher STAT3 activity
increased human VEGF expression, while sequentially
transplanted si-STAT3-transduced hypo-ECFCs displayed
decreased VEGF expression, which is indicative of on-
going angiogenesis, as late as 4 weeks after ECFC trans-
plantation. In addition, mice injected with hypo-ECFCs
exhibited enhanced neovascularization. These findings, in
conjunction with the upregulation of angiogenic cyto-
kines, are consistent with the known vasculogenic mecha-
nisms of ECFCs. Our findings demonstrate the potential
clinical applicability of hypoxia-stimulated ECFCs as a
novel therapeutic neovascularization strategy in ischemic
diseases.
In this study, we investigated ex vivo culture conditions
for the enhancement of the proliferative, clonogenic po-
tential and prevention of ischemic stress-induced apop-
tosis in human ECFCs. The optimized ex vivo culture
conditions consequently promoted robust cell survival
and rapid functional cellular repair in a hindlimb ischemia
cell transplantation model. The techniques and strategies
developed here will be useful in determining the require-
ments of transplanted human ECFCs for in vivo survival,
recruitment to areas with hypoxic damage, and the initi-
ation of endogenous repair. As a result of these studies,
we will gain a better understanding of how injected stem
cells are recruited to damaged tissue to enhance revascu-
larization by endogenous cells.Conclusions
To our knowledge, this study shows for the first time
that hypo-ECFCs enhance the recovery of cells from
vascular injury by modulating the STAT3/BCL3 axis via
VEGF expression (Fig. 8). The therapeutic efficiency of
ECFCs can thus be controlled by modifying the culture
conditions or activation of the STAT3/BCL3 pathway,providing insights into the bioactivity circuit needed for
ECFC therapy that will improve efficiency in clinical
applications.
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